Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?

Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER.

J Infect Dis. 2011 Aug 15;204(4):562-5. doi: 10.1093/infdis/jir342.

2.

Prevalence of HPV infection among females in the United States.

Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE.

JAMA. 2007 Feb 28;297(8):813-9.

PMID:
17327523
3.

Sociodemographic factors associated with high-risk human papillomavirus infection.

Kahn JA, Lan D, Kahn RS.

Obstet Gynecol. 2007 Jul;110(1):87-95. Erratum in: Obstet Gynecol. 2007 Sep;110(3):713.

PMID:
17601901
4.

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER.

J Infect Dis. 2013 Aug 1;208(3):385-93. doi: 10.1093/infdis/jit192. Epub 2013 Jun 19.

5.

Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA.

Wien Klin Wochenschr. 2008;120(21-22):666-71. doi: 10.1007/s00508-008-1093-3.

PMID:
19116707
6.

Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE.

J Infect Dis. 2011 Aug 15;204(4):566-73. doi: 10.1093/infdis/jir341.

7.

Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER.

J Infect Dis. 2009 Oct 1;200(7):1059-67. doi: 10.1086/604729.

8.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

9.

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.

Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, Beddows S, Gill ON.

Vaccine. 2013 Dec 17;32(1):26-32. doi: 10.1016/j.vaccine.2013.10.085. Epub 2013 Nov 6.

10.

Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity.

Figueroa JP, Ward E, Luthi TE, Vermund SH, Brathwaite AR, Burk RD.

Sex Transm Dis. 1995 Mar-Apr;22(2):114-8.

PMID:
7624812
11.

Prevalence of HPV After Introduction of the Vaccination Program in the United States.

Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER.

Pediatrics. 2016 Mar;137(3):e20151968. doi: 10.1542/peds.2015-1968. Epub 2016 Feb 22.

PMID:
26908697
12.

Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008.

Taylor LD, Hariri S, Sternberg M, Dunne EF, Markowitz LE.

Prev Med. 2011 May;52(5):398-400. doi: 10.1016/j.ypmed.2010.11.006. Epub 2010 Nov 23.

PMID:
21108962
13.

Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991--1994.

Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE.

Sex Transm Dis. 2008 Mar;35(3):298-303.

PMID:
18091027
14.

Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.

Dunne EF, Klein NP, Naleway AL, Baxter R, Weinmann S, Riedlinger K, Fetterman B, Steinau M, Scarbrough MZ, Gee J, Markowitz LE, Unger ER.

Cancer Causes Control. 2013 Feb;24(2):403-7. doi: 10.1007/s10552-012-0085-9. Epub 2013 Jan 5.

PMID:
23292130
15.

Human papillomavirus vaccine and sexual behavior among adolescent and young women.

Liddon NC, Leichliter JS, Markowitz LE.

Am J Prev Med. 2012 Jan;42(1):44-52. doi: 10.1016/j.amepre.2011.09.024.

PMID:
22176845
16.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

17.

Prevalence and incidence of HPV genital infection in women.

Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A.

Sex Transm Dis. 2009 Nov;36(11):696-703. doi: 10.1097/OLQ.0b013e3181ad25ff.

PMID:
19652630
18.

Human papillomavirus infection: epidemiology and pathophysiology.

Steben M, Duarte-Franco E.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S2-5. Review.

PMID:
17938014
19.

Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia.

Bedoya AM, Gaviria AM, Baena A, Borrero M, Duarte DF, Combita AL, Castaño J, Grisales H, Sánchez GI.

Int J Gynecol Cancer. 2012 Feb;22(2):303-10. doi: 10.1097/IGC.0b013e31823c2469.

PMID:
22228426
20.

Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.

Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L.

Prev Med. 2009 May;48(5):426-31. doi: 10.1016/j.ypmed.2008.11.010. Epub 2008 Dec 6.

PMID:
19100762
Items per page

Supplemental Content

Write to the Help Desk